241 related articles for article (PubMed ID: 8402512)
1. Impact of clinical trial protocols on patient care systems at the University of Texas M.D. Anderson Cancer Center.
Huber SL
Cancer; 1993 Nov; 72(9 Suppl):2824-7. PubMed ID: 8402512
[TBL] [Abstract][Full Text] [Related]
2. Reimbursement issues facing patients, providers, and payers.
Antman K
Cancer; 1993 Nov; 72(9 Suppl):2842-5. PubMed ID: 8402516
[TBL] [Abstract][Full Text] [Related]
3. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness and reimbursement in patient care.
Antman KH; Aledort LM; Yarbro J; Wilensky G; Wojcik S; Monaco GP; Windham S
Semin Hematol; 1989 Jul; 26(3 Suppl 3):32-45. PubMed ID: 2508228
[TBL] [Abstract][Full Text] [Related]
5. The impact of clinical trial protocols on patient care in a community hospital.
McKenna RJ
Cancer; 1993 Nov; 72(9 Suppl):2828-33. PubMed ID: 8402513
[TBL] [Abstract][Full Text] [Related]
6. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
7. Third-party payers and the cost of biomedical research.
Iltis AS
Kennedy Inst Ethics J; 2005 Jun; 15(2):135-60. PubMed ID: 16149205
[TBL] [Abstract][Full Text] [Related]
8. Funding oncology clinical trials: are cooperative group trials sustainable?
Seow HY; Whelan P; Levine MN; Cowan K; Lysakowski B; Kowaleski B; Snider A; Xu RY; Arnold A
J Clin Oncol; 2012 May; 30(13):1456-61. PubMed ID: 22454412
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project.
Bennett CL; Stinson TJ; Vogel V; Robertson L; Leedy D; O'Brien P; Hobbs J; Sutton T; Ruckdeschel JC; Chirikos TN; Weiner RS; Ramsey MM; Wicha MS
J Clin Oncol; 2000 Aug; 18(15):2805-10. PubMed ID: 10920127
[TBL] [Abstract][Full Text] [Related]
10. Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center.
Biswas S; Liu DD; Lee JJ; Berry DA
Clin Trials; 2009 Jun; 6(3):205-16. PubMed ID: 19528130
[TBL] [Abstract][Full Text] [Related]
11. Greeting cards combat cancer. Pediatric patients design holiday cards and raise money. M.D. Anderson Cancer Center, Houston, TX.
Profiles Healthc Mark; 1992; (49):50-4. PubMed ID: 10122278
[No Abstract] [Full Text] [Related]
12. Managing high cost and biotech drugs: two institutions' perspectives.
Dana WJ; McWhinney B
Hosp Formul; 1994 Sep; 29(9):638-45. PubMed ID: 10137060
[TBL] [Abstract][Full Text] [Related]
13. Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update.
Tidwell RSS; Peng SA; Chen M; Liu DD; Yuan Y; Lee JJ
Clin Trials; 2019 Dec; 16(6):645-656. PubMed ID: 31450957
[TBL] [Abstract][Full Text] [Related]
14. Cost considerations as potential barriers to cancer treatment.
Guidry JJ; Aday LA; Zhang D; Winn RJ
Cancer Pract; 1998; 6(3):182-7. PubMed ID: 9652250
[TBL] [Abstract][Full Text] [Related]
15. Incremental treatment costs in national cancer institute-sponsored clinical trials.
Goldman DP; Berry SH; McCabe MS; Kilgore ML; Potosky AL; Schoenbaum ML; Schonlau M; Weeks JC; Kaplan R; Escarce JJ
JAMA; 2003 Jun; 289(22):2970-7. PubMed ID: 12799405
[TBL] [Abstract][Full Text] [Related]
16. A large private university hospital system. The Johns Hopkins Oncology Center.
Lenhard RE
Cancer; 1993 Nov; 72(9 Suppl):2820-3. PubMed ID: 8402511
[TBL] [Abstract][Full Text] [Related]
17. Expanding Local Cancer Clinical Trial Options: Analysis of the Economic Impact of the Midwest Cancer Alliance in Kansas.
Gafford JA; Gurley-Calvez T; Krebill H; Lai SM; Christiadi ; Doolittle GC
Acad Med; 2017 Sep; 92(9):1274-1279. PubMed ID: 28253204
[TBL] [Abstract][Full Text] [Related]
18. Ethical and financial considerations in third-party support of investigational cancer therapies.
Young FE
Cancer; 1993 Nov; 72(9 Suppl):2854-8. PubMed ID: 8402519
[TBL] [Abstract][Full Text] [Related]
19. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
